Undisclosed pan-KRAS degrader
/ Arvinas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 24, 2026
Anticipated Upcoming Milestones and Expectations
(GlobeNewswire)
- "ARV-6723: Oral PROTAC HPK1 degrader: Initiate Phase 1 clinical trial in patients with advanced solid tumors (mid-2026, pending regulatory feedback). ARV-6723 is Arvinas’ first immuno-oncology clinical candidate; Present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in IO-resistant models compared to standard of care checkpoint inhibition. (1H 2026)....Present preclinical data evaluating the activity and selectivity of novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors (AACR-RAS, March 2026); Present preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes (1H 2026)."
New P1 trial • Preclinical • Solid Tumor
1 to 1
Of
1
Go to page
1